Urigen Pharmaceuticals, Inc.
27 Maiden Lane
Suite 595
San Francisco,
CA 94108
United States - Map
Phone: 415-781-0350
Fax: 415-781-0385
Web Site: http://www.urigen.com
| Urigen Pharmaceuticals, Inc., a specialty pharmaceutical company, develops and commercializes therapeutic products for urological disorders. Its products include URG101, which completed Phase II clinical trial for the treatment of painful bladder syndrome/interstitial cystitis in men and women; and URG301, a proprietary dosage form of an approved drug, which targets a female urethral suppository for urethritis and nocturia. It also has license agreements with the University of California, San Diego, and Kalium, Inc. for certain patent rights. Urigen Pharmaceuticals is headquartered in San Francisco, California. |
|
| Key Statistics |
| |
| | Pay | Exercised | Dr. William J. Garner M.D., 43
Chief Exec. Officer, Pres |
$
250.00K |
$
0 | Dr. C. Lowell Parsons MD, 65
Scientific Founder, Member of Scientific Advisory Board |
$
0 | N/A | Mr. Martin E. Shmagin CPA, 59
Chief Financial Officer, Principal Accounting Officer |
$
225.00K |
$
0 | Mr. Terry M. Nida , 60
Consultant |
$
62.00K |
$
0 | Dr. Dennis H. Giesing Ph.D., 57
Consultant |
$
73.00K |
$
0 |
|
|
|
Dollar amounts are as of
31-Dec-09
and compensation values are for the last fiscal
year ending on that date. "Pay" is salary, bonuses, etc. "Exercised" is the value of
options exercised during the fiscal year.
| |
|
0.18% Nasdaq 
0.42%
Profile
